Literature DB >> 21812106

Basal levels of CD34 positive cells in peripheral blood differ between individuals and are stable for 18 months.

Lisa Eidenschink1, Gere DiZerega, Kathy Rodgers, Mark Bartlett, Denise A Wells, Michael R Loken.   

Abstract

BACKGROUND: Detection of basal levels of CD34 progenitor cells is a rare event analysis enumerating cells down to 1 cell/μl. A reproducible analytic approach was used in three independent clinical trials in which multiple sequential assays were obtained from the same individual.
METHODS: A 4 color panel combining, HLA-DR, CD34, CD45, and CD11b was used in a dual platform analysis to quantify CD34 progenitor cells in peripheral blood, with quality control focused at the lowest measurements (i.e., basal levels), where assay error is greatest.
RESULTS: Repeat testing of individuals every 4 h over the course of 6 days provided a unique opportunity to assess the precision of the analytic technique and identified basal differences between individuals. In a second study, the basal levels were stable for 10 weeks while in a third study the individual differences were maintained for 18 months. This approach was then used to monitor the kinetics of mobilization of CD34 cells following G-CSF stimulation every 4 h.
CONCLUSIONS: The differences between individuals in basal levels of CD34 were shown to be a biologic constant, stable for 18 months and not a result of the variability of the assay, shown by low coefficients of variation for each individual. These results can be used to augment a quality control program by monitoring individuals over time to establish intra and inter-laboratory assay precision. In addition, the response of six individuals to G-CSF demonstrated differences in absolute numbers of mobilized CD34 progenitor cells but showed identical kinetics, peaking at 80-110 h.
Copyright © 2011 International Clinical Cytometry Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21812106     DOI: 10.1002/cyto.b.20611

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  7 in total

Review 1.  Cellular players of hematopoietic stem cell mobilization in the bone marrow niche.

Authors:  Joshua Tay; Jean-Pierre Levesque; Ingrid G Winkler
Journal:  Int J Hematol       Date:  2016-12-10       Impact factor: 2.490

2.  Telocytes play a key role in prostate tissue organisation during the gland morphogenesis.

Authors:  Bruno D A Sanches; Juliana S Maldarine; Bruno C Zani; Guilherme H Tamarindo; Manoel F Biancardi; Fernanda C A Santos; Paula Rahal; Rejane M Góes; Sérgio L Felisbino; Patricia S L Vilamaior; Sebastião R Taboga
Journal:  J Cell Mol Med       Date:  2017-08-24       Impact factor: 5.310

3.  Multiparametric Whole Blood Dissection: A one-shot comprehensive picture of the human hematopoietic system.

Authors:  Luca Basso-Ricci; Serena Scala; Raffaella Milani; Maddalena Migliavacca; Attilio Rovelli; Maria Ester Bernardo; Fabio Ciceri; Alessandro Aiuti; Luca Biasco
Journal:  Cytometry A       Date:  2017-06-13       Impact factor: 4.355

4.  PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen®): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers.

Authors:  Hsuan-Ming Yao; Faith D Ottery; Troy Borema; Stuart Harris; Jeffrey Levy; Tom B May; Shahrzad Moosavi; Jeffrey Zhang; Martin Summers
Journal:  BioDrugs       Date:  2019-04       Impact factor: 5.807

5.  Can mobilization of bone marrow stem cells be an alternative regenerative therapy to stem cell injection in a rat model of chronic kidney disease?

Authors:  Shereen Morsy; Mona F Mansour; Mohamed Abdo; Yasser El-Wazir
Journal:  Physiol Rep       Date:  2022-09

6.  Combined intermittent hypobaric hypoxia and muscle electro-stimulation: a method to increase circulating progenitor cell concentration?

Authors:  Luisa Corral; Casimiro Javierre; Juan Blasi; Ginés Viscor; Antoni Ricart; Josep Lluis Ventura
Journal:  J Transl Med       Date:  2014-06-19       Impact factor: 5.531

7.  Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.

Authors:  Farid Boulad; Tsiporah Shore; Koen van Besien; Caterina Minniti; Mihaela Barbu-Stevanovic; Sylvie Wiener Fedus; Fabiana Perna; June Greenberg; Danielle Guarneri; Vijay Nandi; Audrey Mauguen; Karina Yazdanbakhsh; Michel Sadelain; Patricia A Shi
Journal:  Haematologica       Date:  2018-02-01       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.